Skip to main content

Vendor News Article

Catch up on the latest deals and news

The Wamberg Genomic Advisors Cancer Patient Report

  • 2019-01-09
  • Author: Mandy Yeganegi

Cancer Guardian™ powered by Wamberg Genomic Advisors (WGA) is the newest endorsed supplier of the Biocom Purchasing Group and our partner in genomics. The Wamberg Genomic Advisors Cancer Patient Report is based on a survey of 204 American cancer patients and their non-professional family/friend advocates. The results of the survey are the perceptions of patients and their advocates and not results from clinicians. The press release for this report can be found here.

To read the full report, click here>>

It has been reported by the American Cancer Society that the death rate of cancer has declined over the past two decades. The most recent available data from 2015 reveals the cancer death rate for all US adults fell 26 percent from its peak in 1991, or 2.4 million deaths averted. The improvement in averting cancer mortality is mostly due to steady declines in smoking and advances in early detection and treatment. Improvement in averting cancer mortality is expected through 2018. A total of 1,735,350 new cancer cases and 609,640 cancer deaths are projected to occur in the United States in 2018.

Corroborating statistics from the US Centers for Disease Control and Prevention (CDC), show that the number of new cancer cases is expected to increase from about 1.5 million per year in 2010 to 1.9 million per year in 2020, while the rate of people who die from cancer is expected to decrease from about 171 per 100,000 people in 2010 to 151 per 100,000 people in 2020. As the number of new cancer cases continues to increase every year as a greater number of people survive into old age, cancer is projected to overtake heart disease as the number one cause of death before 2030. Irrespective of improved survival rates, a diagnosis of cancer is still devastating news for an individual and their family.

While great progress has been made to lower cancer death rates through smoking cessation and early detection, it remains equally and vitally important for those people diagnosed to access th most effective treatments faster than ever. The human genome is the instruction manual, comprised of DNA, that contains the information that allows a person to grow and develop. Certain damage to a person’s genome can result in disease, including cancer, and understanding the changes at the genomic level that led to a cancer enables true personalization of therapy. The latest advances in cancer DNA testing, and other cancer support services comprise the leading approaches to be as effective as possible in cancer treatment and therapy. Rapidly reaching and delivering leading approaches to 100 percent of cancer patients can help in the continued averting of cancer deaths.

While many cancer patients believe they are getting excellent care and support, survey results indicate that we are not providing all people diagnosed with cancer fast access to the most effective treatments, including professional support and guidance from diagnosis through treatment. The survey reports results of cancer patients’ responses regarding comprehensive cancer care in three areas:
  1. Finding a treatment/solution (diagnosis): Almost half (47 percent) of individuals dealing directly with cancer said there was “no knowledgeable advocate to help” in finding an effective treatment/ solution for cancer.
  2. Disease management: Respondents wished there was more personalized support in managing the disease with 35 percent wishing another cancer expert was there as an advocate, and 36 percent wanting better support in understanding long-term side effects of the treatment.
  3. Support after surgery/chemotherapy/radiation: Seventy percent (70 percent) of the respondents were cases that required surgery and 47 percent underwent radiation and/or chemotherapy treatments. Twenty-six percent (26 percent) of respondents said that they wanted more care and support from health or social services, and 28 percent noted that they did not have enough support during treatment.
The survey underscores the challenges that patients and their families face navigating the U.S. complex health-care system from diagnosis to finding a treatment. Many cancer patients do want more support during diagnosis, treatment, and post-surgery and/or chemo/radiation therapy.

Every cancer patient should have access to a comprehensive cancer support program that includes advanced DNA testing, access to cancer support specialists, and a second opinion to help people during an extremely challenging and often overwhelming time.

Some patients do not have personalized support from well-informed, technically qualified oncology professionals who are familiar with the cancer landscape and the associated challenges of managing and living with cancer. Cancer Support Specialists can be available by phone to counsel and provide compassionate support, as well as case management. In addition, support can include an on-site Nurse Navigator who will attend a patient’s key appointment in-person.

A trusted and knowledgeable patient advocate in the room can help to make sure there is clear understanding about all the possible risks and benefits of cancer therapies. This helps both the patient and the doctor to give the best cancer care possible.

Medical studies have shown that cancer patients who have access to Cancer Nurse Case Managers/ Navigators have less time delay to starting treatment, fewer hospital readmissions, less cancer-related healthcare cost and overall improved patient satisfaction.

Cancer Guardian from Wamberg Genomic Advisors is a leading advancement in personalizing cancer support and treatment. Wamberg Genomic Advisors is dedicated to making genomic-based programs and services, not typically covered by health insurance, available at prices everyone can afford.

To read the full report, click here>>